How To Use CPT Code 3315F

CPT code 3315F describes the assessment of estrogen or progesterone receptors in tumor cells of female patients with breast cancer. This article will cover the description, procedure, qualifying circumstances, appropriate usage, documentation requirements, billing guidelines, historical information, and examples.

1. What is CPT Code 3315F?

CPT 3315F can be used to assess the presence of estrogen or progesterone receptors in tumor cells of female patients with breast cancer. These receptors are cell proteins that bind to specific molecules and play a role in the growth of certain breast cancer cells. By determining if the tumor is estrogen or progesterone receptor positive (ER+ or PR+), healthcare providers can prescribe medications that interfere with the production or utilization of estrogen, thereby inhibiting cancer growth.

2. Official Description

The official description of CPT code 3315F is: ‘Estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer (ONC).’ This code is used to report the assessment of estrogen or progesterone receptors in tumor cells of female patients with breast cancer.

3. Procedure

1. The healthcare provider assesses the presence of estrogen or progesterone receptors in tumor cells of female patients with breast cancer.
2. This assessment helps determine the appropriate treatment plan for the patient based on the presence or absence of these receptors.
3. If the tumor is estrogen or progesterone receptor positive (ER+ or PR+), healthcare providers may prescribe medications such as tamoxifen or aromatase inhibitors to interfere with the production or utilization of estrogen and prevent cancer growth.
4. The healthcare provider documents the presence of ER+ or PR+ breast cancer and the date of the assessment in the patient’s healthcare record.

4. Qualifying circumstances

CPT 3315F is used for female patients, 18 years of age or older, who have breast cancer and whose tumor contains estrogen or progesterone receptors. The presence of these receptors determines the treatment approach, as medications that interfere with estrogen production or utilization are prescribed for ER+ or PR+ breast cancer.

5. When to use CPT code 3315F

CPT code 3315F should be used when assessing the presence of estrogen or progesterone receptors in tumor cells of female patients with breast cancer. It is important to use this code when the tumor contains these receptors, as it influences the treatment plan and the prescription of medications that target estrogen.

6. Documentation requirements

To support a claim for CPT code 3315F, the healthcare provider must document the following information:

• Patient’s diagnosis of breast cancer
• Presence of estrogen or progesterone receptors in tumor cells
• Date of the assessment

7. Billing guidelines

When billing for CPT code 3315F, ensure that the patient is a female, 18 years of age or older, with breast cancer and a tumor that contains estrogen or progesterone receptors. This code should be reported for the assessment of these receptors in tumor cells. It is important to follow any specific billing guidelines provided by the payer or coding guidelines.

8. Historical information

CPT code 3315F was added to the Current Procedural Terminology system on January 1, 2009. There have been no updates or changes to the code since its addition.

9. Examples

1. A healthcare provider assessing the presence of estrogen or progesterone receptors in tumor cells of a female patient with breast cancer.
2. A pathologist analyzing breast cancer tissue for the presence of estrogen or progesterone receptors in a female patient.
3. A medical oncologist determining the treatment approach for a female patient with ER+ or PR+ breast cancer based on the assessment of estrogen or progesterone receptors.
4. A surgeon discussing the results of the receptor assessment with a female patient and explaining the implications for her treatment plan.
5. A radiologist reviewing imaging studies to identify the presence of estrogen or progesterone receptors in tumor cells of a female patient with breast cancer.
6. A nurse documenting the results of the receptor assessment in the healthcare record of a female patient with breast cancer.
7. An oncology nurse educating a female patient about the significance of estrogen or progesterone receptor status in breast cancer and its impact on treatment options.
8. A healthcare provider discussing the assessment of estrogen or progesterone receptors with a female patient and answering any questions or concerns she may have.
9. A medical researcher conducting a study on the correlation between estrogen or progesterone receptor status and treatment outcomes in female patients with breast cancer.
10. A genetic counselor explaining the role of estrogen or progesterone receptors in breast cancer to a female patient with a family history of the disease.